• Login
    • Advanced search
    • Title
    • Channel
    • Module
  • Home
  • Industry
    •  

      • Aerospace, Defense, and Government Services
      • Automotive and Mobility
      • Consumer
      • Manufacturing and Industrials
      • Education
      • Energy and Natural Resources
      • Financial Institutions
    •  

      • Insurance
      • Life Sciences and Health Care
      • Private Capital
      • Real Estate
      • Sports, Media and Entertainment
      • Technology and Telecoms
      • Transportation and Logistics
  • Practice
    • Corporate & Finance

      • Banking and Loan Finance
      • Business Restructuring and Insolvency
      • Capital Markets
      • Corporate Governance and Public Company Representation
      • Digital Assets and Blockchain
      • Infrastructure, Energy, Resources, and Projects
      • Leveraged and Acquisition Finance
      • Mergers and Acquisitions
      • Pensions
      • Private Equity, Venture Capital and Investment Funds
      • Real Estate
      • Real Estate Investment Trusts (REITs)
      • Tax
      • Transfer Pricing
    • Global Regulatory

      • Administrative and Public Law
      • Antitrust and Competition
      • Communications, Internet, and Media
      • Education
      • Energy Regulatory
      • Environment and Natural Resources
      • Financial Services
      • Food Law
      • Gaming Law
      • Government Contracts and Public Procurement
      • Government Relations and Public Affairs
      • Health
      • Immigration
      • International Trade and Investment
      • Medical Device and Technology Regulatory
      • New Nuclear
      • Pharmaceuticals and Biotechnology Regulatory
      • Privacy and Cybersecurity
      • Space and Satellite
      • Strategic Operations, Agreements and Regulation
      • Transportation Regulatory
    • Intellectual Property

      • Copyright
      • Designs
      • Domain Names
      • IP and Technology Transactions
      • IP Enforcement
      • Patents
      • Trade Secrets and Confidential Know-how
      • Trademarks and Brands
      • Unfair Competition
    • Litigation, Arbitration, and Employment

      • Business and Human Rights
      • Construction and Engineering
      • Corporate and Securities Litigation
      • Employment
      • International Arbitration
      • Investigations, White Collar, and Fraud
      • Products Law
      • Risks, Disputes, and Litigation
  • Comparative guides
  • Engage Premium
  • Login
  • Register
Hogan Lovells Engage 5.7.16
      • Title
      • Channel
      • Module
    • Hit ENTER to search in content
    • Advanced search
    • Login
  • Home
  • Industry
    •  

      • Aerospace, Defense, and Government Services
      • Automotive and Mobility
      • Consumer
      • Manufacturing and Industrials
      • Education
      • Energy and Natural Resources
      • Financial Institutions
    •  

      • Insurance
      • Life Sciences and Health Care
      • Private Capital
      • Real Estate
      • Sports, Media and Entertainment
      • Technology and Telecoms
      • Transportation and Logistics
  • Practice
    • Corporate & Finance

      • Banking and Loan Finance
      • Business Restructuring and Insolvency
      • Capital Markets
      • Corporate Governance and Public Company Representation
      • Digital Assets and Blockchain
      • Infrastructure, Energy, Resources, and Projects
      • Leveraged and Acquisition Finance
      • Mergers and Acquisitions
      • Pensions
      • Private Equity, Venture Capital and Investment Funds
      • Real Estate
      • Real Estate Investment Trusts (REITs)
      • Tax
      • Transfer Pricing
    • Global Regulatory

      • Administrative and Public Law
      • Antitrust and Competition
      • Communications, Internet, and Media
      • Education
      • Energy Regulatory
      • Environment and Natural Resources
      • Financial Services
      • Food Law
      • Gaming Law
      • Government Contracts and Public Procurement
      • Government Relations and Public Affairs
      • Health
      • Immigration
      • International Trade and Investment
      • Medical Device and Technology Regulatory
      • New Nuclear
      • Pharmaceuticals and Biotechnology Regulatory
      • Privacy and Cybersecurity
      • Space and Satellite
      • Strategic Operations, Agreements and Regulation
      • Transportation Regulatory
    • Intellectual Property

      • Copyright
      • Designs
      • Domain Names
      • IP and Technology Transactions
      • IP Enforcement
      • Patents
      • Trade Secrets and Confidential Know-how
      • Trademarks and Brands
      • Unfair Competition
    • Litigation, Arbitration, and Employment

      • Business and Human Rights
      • Construction and Engineering
      • Corporate and Securities Litigation
      • Employment
      • International Arbitration
      • Investigations, White Collar, and Fraud
      • Products Law
      • Risks, Disputes, and Litigation
  • Comparative guides
  • Engage Premium
  • Login
  • Register
  1. News
  2. Top 10 things biotech employers need to know about COVID-19 vaccines and returning to the office

Top 10 things biotech employers need to know about COVID-19 vaccines and returning to the office

15 February 2021
    • Share by email
    • Share on
    • Twitter
    • LinkedIn
    • Get link
    • Get QR Code
    • Download
    • Print

On February 2, Hogan Lovells partners Melissa Bianchi, David Horowitz, and George Ingham presented a webinar to the Biotechnical Innovation Organization (BIO) on “What Biotech Employers Need to Know about COVID Vaccines and Returning to the Office.” Below are the top 10 considerations discussed in the webinar, and a full video recording containing additional details is available here.

  1. According to current Equal Employment Opportunity Commission (EEOC) guidance, employers are likely able to implement mandatory vaccination policies, however, employers must consider whether they should do so. Employers must consider factors such as the availability of vaccines, the need to provide accommodations to objecting employees, and state and local law issues.

  2. Employers that impose mandatory vaccination programs must be prepared to process exemption requests on the basis of disability, pregnancy, and sincerely-held religious belief. Due to the broad definitions of disability and sincerely-held religious belief, and the legal framework for pregnancy accommodations, employers implementing mandatory programs may face a wide variety of requests that may require analysis to determine whether a “reasonable accommodation” can be made.

  3. The fact that the vaccine has been authorized under an Emergency Use Authorization (EUA) does not prohibit an employer from imposing consequences for refusing to be vaccinated.

  4. Employers can ask employees vaccine-related questions. Questions should be for a clear and legitimate business purpose that is documented, should avoid questions about protected class and genetic information (including family information), and should be maintained confidentially and separate from normal personnel files. For example, asking an employee if the employee is vaccinated, or asking for proof is acceptable, but asking the employee why the employee did not get vaccinated is risky.

  5. Employers should take care before providing information to management about who has been vaccinated, and aggregate and anonymize data so that managers cannot identify which individuals have or have not been vaccinated. Employers who obtain vaccination information from a health plan or health care provider, should note that HIPAA or state privacy laws may apply, requiring employee authorization or consent for the disclosure.

  6. Employers with voluntary vaccination programs have more leeway to set up on-site clinics where the employer or a third party provides vaccines to employees. Employers with mandatory programs can only do this with respect to employees that it has “a reasonable belief, based on objective evidence, that [the] employee who does not answer the questions and, therefore, does not receive a vaccination, will pose a direct threat to the health or safety of her or himself or others.”

  7. Employers that seek to adopt different vaccination rules for different segments of the workplace (e.g., a mandatory program only applying to certain employees) must ensure that similarly-situated employees are treated the same to avoid discrimination claims.

  8. An employer generally can require non-employees (e.g., independent contractors, visitors) to be vaccinated to come on site, as non-employees are not covered by many of the applicable protections that cover employees. That said, employers should consider state and local law which can sometimes grant independent contractors the right to reasonable accommodations.

  9. Currently, employers should not make major changes to business operations based on workplace vaccination rates. New guidance from the federal Occupational Safety and Health Administration expressly states that employers should “not distinguish between workers who are vaccinated and those who are not” in terms of safety measures.

  10. Employers should consider their strategy for encouraging employees to get vaccinated, including leading by example, educating employees about vaccines and when they are available, and considering whether they wish to provide incentives to employees who are vaccinated.

 

For more information about COVID-19 vaccines and your workforce, please contact the Hogan Lovells lawyer with whom you regularly work.

Contacts
Melissa Bianchi
Partner
Washington, D.C.
David Horowitz
Partner
Washington, D.C.
George Ingham
Partner
Northern Virginia
Related Materials
Bacteria%20(COVID-19%20primary%20image)

COVID-19 Report for Life Sciences and Health Care Companies (February 2021)

girl_virtualreality_googles_1218

Increased use of virtual tools, optimized inspectional activities, & enhanced supply chain oversight

Domain Names and Internet Governance, February 2019 - computer, code, screen

2020 OPDP Wrap-up: FDA monitoring drug manufacturers’ use of online communication platforms

Keywords vaccine, return to office, office, employment, labor, EEOC, employer, contractor, sincerely-held belief, HIPAA, osha, Occupational Safety and Health Administration
Languages English
Topics COVID-19, Health Privacy, Biologics and Biosimilars, Cell, Tissue, and Gene Therapies (CTGT)
Countries United States
Delete Comment ?

Are you sure want to delete comment ?

Get link
Embed
Share by email
Get QR Code

Scan this QR Code to share this content

  • Contact us
  • Disclaimer
  • Privacy
  • Cookies
  • Legal Notices
  • Terms of Use

 

This website is operated by Hogan Lovells International LLP, whose registered office is at Atlantic House, Holborn Viaduct, London, EC1A 2FG. For further details of Hogan Lovells International LLP and the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses ("Hogan Lovells"), please see our Legal Notices page. © 2022 Hogan Lovells.

Attorney advertising. Prior results do not guarantee a similar outcome.

Thomson Reuters HighQ Logo
© 2023 Hogan Lovells | Privacy Policy | Terms of Service